AIkido Pharma Inc. [AIKI] fell -21.26% so far this year. What now?

Related

Share

AIkido Pharma Inc. [NASDAQ: AIKI] gained 30.05% or 0.1 points to close at $0.46 with a heavy trading volume of 23571450 shares. The company report on May 4, 2022 that AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider Discord, Inc..

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Discord Reportedly Interviewing Investment Bankers About Going Public This Year.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company has secured an early equity interest in privately-held Discord, Inc. (https://discord.com/), a social communications platform provider that is particularly popular with gamers.

It opened the trading session at $0.351, the shares rose to $0.58 and dropped to $0.351, the range by which the price of stock traded the whole day. The daily chart for AIKI points out that the company has recorded -47.73% loss over the past six months. However, it is still -53.33% lower than its most recent low trading price.

If we look at the average trading volume of 1.06M shares, AIKI reached to a volume of 23571450 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about AIkido Pharma Inc. [AIKI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AIKI shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AIKI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for AIkido Pharma Inc. is set at 0.04 The Price to Book ratio for the last quarter was 0.41, with the Price to Cash per share for the same quarter was set at 0.94.

Trading performance analysis for AIKI stock

AIkido Pharma Inc. [AIKI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 45.53. With this latest performance, AIKI shares gained by 1.69% in over the last four-week period, additionally sinking by -47.73% over the last 6 months – not to mention a drop of -50.08% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIKI stock in for the last two-week period is set at 69.14, with the RSI for the last a single of trading hit 79.44, and the three-weeks RSI is set at 61.95 for AIkido Pharma Inc. [AIKI]. The present Moving Average for the last 50 days of trading for this stock 0.3979, while it was recorded at 0.3653 for the last single week of trading, and 0.6385 for the last 200 days.

AIkido Pharma Inc. [AIKI]: A deeper dive into fundamental analysis

Return on Equity for this stock declined to -10.93, with Return on Assets sitting at -10.77.

AIkido Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 85.70 and a Current Ratio set at 85.70.

An analysis of insider ownership at AIkido Pharma Inc. [AIKI]

There are presently around $3 million, or 8.90% of AIKI stock, in the hands of institutional investors. The top three institutional holders of AIKI stocks are: VANGUARD GROUP INC with ownership of 4,125,723, which is approximately -0.27% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 1,278,760 shares of the stock with an approximate value of $0.45 million in AIKI stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.26 million in AIKI stock with ownership of nearly 0% of the company’s market capitalization.

Positions in AIkido Pharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 12 institutional holders increased their position in AIkido Pharma Inc. [NASDAQ:AIKI] by around 954,417 shares. Additionally, 11 investors decreased positions by around 721,681 shares, while 5 investors held positions by with 6,239,598 shares. The mentioned changes placed institutional holdings at 7,915,696 shares, according to the latest SEC report filing. AIKI stock had 9 new institutional investments in for a total of 919,769 shares, while 5 institutional investors sold positions of 676,697 shares during the same period.